RecruitingPhase 2NCT07254754
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Mariana Bastos-OreiroHospital General Universitario Gregorio Marañón
- Intervention
- Axicabtagene Ciloleucel(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2031
Study locations (15)
- Complejo Hospitalario Universitario A Coruña, A Coruña, A Coruña, Spain
- Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain
- Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
- Hospital Universitario de Salamanca, Salamanca, Castille and León, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain
- Hospital Clinic i Provincial de Barcelona, Barcelona, Catalonia, Spain
- Institut Català d'oncologia de L'Hospitalet, L'Hospitalet de Llobregat, Catalonia, Spain
- Hospital Universitario Donostia, San Sebastián, Gipuzkoa, Spain
- Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
- Hospital General Universitario Morales Meseguer, Murcia, Murcia, Spain
- Clínica Universidad de Navarra, Pamplona, Navarre, Spain
- Hospital Universitario Virgen del Rocío, Seville, Sevilla, Spain
- Hospital Clínico Universitario de Valencia, Valencia, Valencia, Spain
Collaborators
Kite, A Gilead Company · Evidenze Health España (CRO)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07254754 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGPHASE2NCT05934448Pembro Plus CAR T-cell Therapy in R/R in PMBCLJennifer Crombie, MD
- RECRUITINGPHASE2NCT05633615Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaSWOG Cancer Research Network
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →